Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg
6-month formulation in 44 patients suffering from central precocious puberty. The total study
duration per patient will be 12 months (48 weeks).